DexCom, Inc. (NASDAQ:DXCM) Receives $110.73 Average PT from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus recommendation of “Moderate Buy” by the eighteen analysts that are currently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $104.59.

DXCM has been the topic of several research analyst reports. UBS Group dropped their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Raymond James decreased their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Baird R W downgraded DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by corporate insiders.

Institutional Trading of DexCom

Several large investors have recently made changes to their positions in the company. Intact Investment Management Inc. acquired a new stake in shares of DexCom in the 3rd quarter valued at about $650,000. Ground Swell Capital LLC bought a new position in DexCom in the 3rd quarter valued at about $1,025,000. Van ECK Associates Corp lifted its position in DexCom by 14.0% in the 3rd quarter. Van ECK Associates Corp now owns 20,191 shares of the medical device company’s stock valued at $1,463,000 after acquiring an additional 2,475 shares in the last quarter. Empire Life Investments Inc. bought a new position in DexCom in the 3rd quarter valued at about $5,613,000. Finally, Arcadia Investment Management Corp MI lifted its position in DexCom by 1,111.0% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 19,800 shares of the medical device company’s stock valued at $1,327,000 after acquiring an additional 18,165 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

NASDAQ:DXCM opened at $72.24 on Friday. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The stock’s 50 day moving average price is $69.98 and its two-hundred day moving average price is $96.73. The firm has a market capitalization of $28.73 billion, a price-to-earnings ratio of 46.61, a P/E/G ratio of 2.26 and a beta of 1.18. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.